February 15, 2007 – MedImmune reported that FluMist was more effective than an injected vaccine in children under five; the FDA accepted filings from Merck for use of diabetes drug Januvia as a first-line therapy; Geron said its telomerase cancer drug was effective in pre-clinical tests; Cepheid bought a fellow molecular diagnostics company, Sangtec Molecular Diagnostics of Sweden, for $27 million; Ariad will sell up to $50 million in stock to Azimuth; and OXiGENE reported its drug for myopic macular degeneration met its primary endpoint. The Centient Biotech 200™ rose 2 points to 4077, an increase of .05%. More details...
